|
On Thursday, September 1, CDC recommended the following bivalent booster shots for COVID-19 vaccination:
- Pfizer-BioNTech booster for patients ages 12 and older.
- Moderna booster for patients ages 18 and older.
See the CDC statement.
This recommendation follows FDA's authorization of these products on Wednesday, August 31.
These new boosters are called “bivalent” because they protect against two different COVID-19 strains: the original and the highly contagious omicron variant.
The single-shot bivalent boosters may be administered at least two months following primary or booster vaccination. Look to the CDC resources below for guidance on boosters for people with recent infection.
CDC also encourages coadministration with the flu vaccine.
-
FDA’s authorization simultaneously rescinded the authorization for monovalent boosters, specifically in this statement: “With today’s authorization, the monovalent mRNA COVID-19 vaccines are not authorized as booster doses for individuals 12 years of age and older.”
-
The monovalent (original) vaccines will continue to be used for primary vaccination in patients that have never been vaccinated against COVID-19. Continue to store and use viable monovalent vaccine to administer primary series vaccinations.
|
RESOURCES
These resources can help your health center plan for booster administration. Check them for updates over the coming days.
OPPORTUNITIES TO LEARN MORE
COVID-19 Response Program Office Hours
We’ll discuss the new boosters at next Tuesday’s session (September 6). It will also feature three participants in the HRSA Health Center COVID-19 Therapeutics Program sharing success stories.
Sessions are 1:00-2:00 p.m. ET every other Tuesday. Register one time and you’ll have access to all Office Hour sessions from now until February 2023. Though some information may be geared toward COVID-19 Response Program participants, these sessions are open to all HRSA-supported health centers.
2022-2023 Influenza Vaccination Recommendations and Guidance on Coadministration with COVID-19 Vaccines
CDC’s next Clinician Outreach and Communication Activity (COCA) call will provide updates on the Advisory Committee on Immunization Practices (ACIP) recommendations for the 2022-2023 influenza vaccination season, including information on a new preferential vaccine recommendation for adults ages 65 and older. Speakers will also outline guidance for the coadministration of the influenza and COVID-19 vaccines.
Thursday, September 8
2:00-3:00 p.m. ET
Join the day of the session
The slides and recording will be posted on the call webpage. **CDC offers continuing education (CE) credit for this activity.**
|
